Drugs & Therapy Perspectives

, Volume 23, Issue 11, pp 9–12 | Cite as

The pharmacological treatment of attention-deficit hyperactivity disorder (ADHD) in adolescents is effective and relatively safe

Disease Management

Although the treatment of attention-deficit hyperactivity disorder in adolescents brings new challenges, stimulant and nonstimulant medications are likely to be as effective in adolescents as they are in younger children. To ensure coverage of school and extracurricular activities, the use of longer-acting formulations is often required. The risk of adverse effects appears to be outweighed by the benefits of treatment.

ADHD less prevalent in adolescents …

Attention-deficit hyperactivity disorder (ADHD) has a declining prevalence from childhood to adolescence,[1] although diagnostic criteria may result in the underestimation of its prevalence in adolescents.[2] Although these criteria are sensitive to symptoms in younger children, they may not capture some of the symptoms present in adolescents with persistent ADHD.[2] Problems relating to inattention, rather than to hyperactivity or impulsivity, are those that generally persist into adolescence.[1] Therefore, even if diagnostic...


  1. 1.
    Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157(5): 816–8PubMedCrossRefGoogle Scholar
  2. 2.
    Hazell P. Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations. CNS Drugs 2007; 21 (1) 37-46Google Scholar
  3. 3.
    British Medical Association and the Royal Pharmaceutical Society of Great Britian. British national formulary. No. 53. London: BMJ Publishing Group Ltd and RPS Publishing, 2007 MarGoogle Scholar
  4. 4.
    WoltersKluwer Health Inc. Facts & comparisons 4.0 [online]. Available from URL: [Accessed 2007 Jun 20]
  5. 5.
    Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007; 30(1): 17–26PubMedCrossRefGoogle Scholar
  6. 6.
    Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents: a meta-analysis. CMAJ 2001; 165(11): 1475–88PubMedGoogle Scholar
  7. 7.
    Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: technology appraisal 98. London: National Institute for Health and Clinical Excellence, 2006 MarGoogle Scholar
  8. 8.
    Greenhill LL, Abikoff HB, Aanold E, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 34(10): 1304–13CrossRefGoogle Scholar
  9. 9.
    Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006; 160(2): 82–90CrossRefGoogle Scholar
  10. 10.
    Cox DJ, Humphrey JW, Merkel RL, et al. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 2004; 17(4): 235–9PubMedCrossRefGoogle Scholar
  11. 11.
    Wilens TE, Kratochvil C, Newcorn JH, et al. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006; 45: 149–57PubMedCrossRefGoogle Scholar
  12. 12.
    Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. J Addict Dis 2004; 23(4): 31–40PubMedCrossRefGoogle Scholar
  13. 13.
    Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol 2005; 15(5): 751–63PubMedCrossRefGoogle Scholar
  14. 14.
    Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999; 99(8): 979–82PubMedCrossRefGoogle Scholar
  15. 15.
    El-Zein R, Abdel-Rahman SZ, Hay MJ, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett 2005; 230(2): 284–91PubMedCrossRefGoogle Scholar
  16. 16.
    Selby J, Friedman GD, Fireman BH. Screening precription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989; 49(20): 5736–47PubMedGoogle Scholar
  17. 17.
    Institute for Clinical Systems Improvement. Health care guideline: diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents. 7th ed. [online]. Available from URL: [Accessed 2007 May 11]

Copyright information

© Adis Data Information BV 2007

Personalised recommendations